0000880771-17-000032.txt : 20170308 0000880771-17-000032.hdr.sgml : 20170308 20170308193324 ACCESSION NUMBER: 0000880771-17-000032 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170306 FILED AS OF DATE: 20170308 DATE AS OF CHANGE: 20170308 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blobel Friedhelm CENTRAL INDEX KEY: 0001363213 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 17676440 MAIL ADDRESS: STREET 1: 950 TOWER LANE, SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 certent-form4.xml PRIMARY DOCUMENT X0306 4 2017-03-06 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001363213 Blobel Friedhelm 950 TOWER LANE, SUITE 900 FOSTER CITY CA 94404 1 1 0 0 President & CEO Common Stock 2017-03-06 4 M 0 3087 3.55 A 90613 D Common Stock 2017-03-06 4 S 0 3087 10.2970 D 87526 D Non-Qualified Stock Option (right to buy) 3.55 2017-03-06 4 M 0 3087 0 D 2020-03-05 Common Stock 3087 290400 D Restricted Stock Unit 2017-03-08 4 A 0 20000 0 A 2027-03-08 Common Stock 20000 345000 D Incentive Stock Option (right to buy) 9.65 2017-03-08 4 A 0 10843 0 A 2027-03-08 Common Stock 10843 10843 D Non-Qualified Stock Option (right to buy) 9.65 2017-03-08 4 A 0 129157 0 A 2027-03-08 Common Stock 129157 129157 D The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016. Granted under the Issuer's 2005 Equity Incentive Plan. 25% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer. Granted under the Issuer's 2015 Equity Incentive Plan. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Vesting for such RSUs will occur 25% on March 8, 2018, 25% on March 8, 2019, 25% on March 8, 2020, and 25% on March 8, 2021, contingent upon the executive's continued employment. 25% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer. By: /s/ Wilson W. Cheung, Attorney-in-Fact For: Friedhelm Blobel, Ph.D. 2017-03-08